The Learner Notification
for the 2023 ISHLT Academy Master Class in Pulmonary Hypertension is now available. You can download the document using the button below.
Pulmonary hypertension (PH) is a life-threatening condition commonly encountered in patients with advanced heart and lung disease. Despite significant advances in the field, patients with PH are complex and their management can be challenging. Initial recognition of the PH problem and delay in diagnosis remains an issue and this contributes to the poor long-term survival of these patients. Misidentification of the causes and misclassification of PH leads to poorsurvival rates and inappropriate treatment. In addition, recent important updates to guidelines for diagnosis and treatment will be addressed throughout the course.
This course is intended for members with higher levels of expertise (completed the core curriculum course on PH and/or practice in the treatment of PH for 5 years or more). Pulmonologists, cardiologists, cardiothoracic surgeons, nurse practitioners, nurses, physician assistants and allied health professionals with experience in PH would all benefit from the course. While all members are invited to enroll, Master Classes are primarily designed to be of benefit for health care professionals who are beyond the training stages of their careers. This may be professionals who are seeking additional proficiencies, who wish to understand current areas of controversy, or who desire an update on the current advanced topics of the field. The information presented is intended to provide insights beyond core competencies established in the specialty. This is a forum to allow discussion on Management dilemmas and areas of unmet need in pulmonary vascular medicine, led by an expert faculty.
At the conclusion of this meeting, participants will have improved competence and professional performance in their ability to:
- Understand the management of patients with advanced PAH including right heart failure.
- Identify the challenges in the spectrum of Pulmonary Hypertension (PH) due to left heart disease since it is an increasingly recognized complication.
- Understand PH due to advanced lung disease and the current treatment strategies.
- Understand current diagnostic and management strategies in Chronic Thromboembolic Pulmonary Disease (CTEPD) without PH and with PH (CTEPH).
Accreditation & Credit Designation Statements
The International Society for Heart & Lung Transplantation (ISHLT) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. ISHLT designates this live activity for a maximum of 9.00 AMA PRA Category 1 Credit(s)™ (each Academy is 4.50 AMA PRA Category 1 Credits(s)™)
. Two Academies can be attended on April 18, 2023 for a maximum of 9.00 AMA PRA Category 1 Credit(s)™
. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and International Society for Heart & Lung Transplantation. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Nurses and Pharmacists
Amedco LLC designates this activity for a maximum of 9.00 ANCC contact hours (each Academy has 4.50 ANCC contact hours)
. in the activity.
Pharmacists (ACPE) Credit Designation
Amedco LLC designates this activity for a maximum of 9.00 knowledge-based CPE contact hours. (Each Academy has 4.50 knowledge-based CPE contact hours).
NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of your participation in the activity to meet the deadline for submission to CPE Monitor.